Company: OTSA
Filing Date: 2025-05-23
Form Type: DRS/A
Source: 0001213900-25-047247
Chunk: 160

Company: OTSAW Ltd
Filing Date: 2025-05-23
Form: DRS/A
Chunk 160
---
 Offering. The timing of market entry will depend on factors such as partnership opportunities, market demand, and the successful acquisition of necessary regulatory approvals. In the United States, we have since established an office which is currently staffed with two full -timesales representatives focused on business development and customer outreach. These representatives are actively engaging with potential customers and partners and laying the groundwork for a broader market entry. Over the next 1 to 3 years, we plan to expand our operations in the United States by building a full team, including sales, pre -salesand technical service personnel, with a target headcount of up to 20 employees. In Europe, we currently employ eight full -timeemployees focused on customer outreach and providing service and maintenance services to our customers in the region. Over the next 1 to 3 years, we plan to expand our operations in Europe by increasing the size of our team to 20 employees. In parallel, we are preparing to meet applicable regulatory and certification requirements in the United States and Europe. These include obtaining UL and FCC certifications for the United States market, and CE certification for the European market. We expect to complete these compliance processes as part of our international expansion strategy. In relation to the healthcare facilities management industry, our joint venture with Swisslog Healthcare provides us with an immediate customer base and market access to hospitals and healthcare facilities in Europe and Southeast Asia, which are regions with a particularly high barrier to entry. Swisslog Healthcare’s strong reputation in the healthcare industry, along with the value of its TransCar hospital intralogistics product, are effectively complemented by our existing scalable AMR security patrol and last -miledelivery AMR platforms, UV -Cdisinfection systems and our core software technologies. 100 Additionally, we will further penetrate the healthcare intralogistics markets in Europe and Southeast Asia by upgrading and “future -proofing” the existing TransCar AGV systems with our core software technologies. We are confident in our ability to take advantage of current market opportunities because hospitals worldwide are expected to upgrade their intralogistics systems to solve labor shortage and productivity challenges that were particularly exposed during the COVID -19pandemic. We envision to replace the conventional labor -intensivehigh and low volume intralogistics, disinfection, and security patrol functions in hospital and healthcare facilities with our AI -enabledrobotics and AMR solutions. Furthermore, in addition to the existing use case as a hospital intralogistics solution, with the enhanced capabilities and upgrades, we intend for Transcar 5.0 to